Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16763418 | 1.00 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| Hydrochloric Acid SCHEMBL3090994 | 1.00 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL3099571 | 0.98 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL13149938 | 0.98 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL3099567 | 0.98 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL24593361 | 0.96 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| Hydrochloric Acid SCHEMBL9470146 | 0.91 | MEN1 (0.39) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL9470148 | 0.89 | MEN1 (0.40) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL30278792 | 0.85 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL6736374 | 0.84 | MAPT (0.50) | MEN1KMT2AMAPTALDH1A1PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202850-B2 | Cyclobutyl purine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-3831836-B1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2023-09-06 | — | — | EP | disclosed |
| US-20220242886-A1 | CHEMICAL COMPOUNDS | CANAAN XII L.P. | 2022-08-04 | — | — | US | disclosed |
| US-11306108-B2 | Chemical compounds | BORAH, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3969458-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3831836-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM Corporation (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-20210147456-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2021-05-20 | — | — | US | disclosed |
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3157917-B1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-2258700-A1 | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | Pfizer Products Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | BHATTACHARYA SAMIT K | 2010-09-16 | — | — | US | disclosed |
| EP-2209771-A1 | CYCLOBUTYL CARBOXYLIC ACID DERIVATIVES | Pfizer, Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | BHATTACHARYA SAMIT KUMAR | 2010-05-13 | — | — | US | disclosed |
| US-7671043-B2 | Cycloalkylamino acid derivatives | PFIZER INC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090227641-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER, INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009060278-A1 | CYCLOBUTYL CARBOXYLIC ACID DERIVATIVES | PFIZER INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-2021338-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Products Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | CCND1, CCND2, CCND3 | MEN1 871/4885KMT2A 1433/4885MAPT 3368/4885 |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, SLC29A1 | MEN1 2712/4885KMT2A 4442/4885MAPT 4397/4885 |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCNI, CCNA1, PCNA | MEN1 1531/4885KMT2A 1501/4885MAPT 3088/4885 |
| US-20210147456-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, SLC29A1 | MEN1 2712/4885KMT2A 4442/4885MAPT 4397/4885 |
| US-12202850-B2 | Cyclobutyl purine derivative or salt thereof | SLC28A1, SLC20A1, SLC29A1 | MEN1 2712/4885KMT2A 4442/4885MAPT 4397/4885 |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCND1, CCND2, CCND3 | MEN1 871/4885KMT2A 1433/4885MAPT 3368/4885 |
| US-20220242886-A1 | CHEMICAL COMPOUNDS | JAK2, JAK1, JAK3 | MEN1 1421/4885KMT2A 616/4885MAPT 2460/4885 |
| US-11306108-B2 | Chemical compounds | JAK2, JAK1, JAK3 | MEN1 1421/4885KMT2A 616/4885MAPT 2460/4885 |
| US-20090227641-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCNI, CCNA1, PCNA | MEN1 1531/4885KMT2A 1501/4885MAPT 3088/4885 |
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, ABCB4, SCNN1B | MEN1 4749/4885KMT2A 4776/4885MAPT 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.